261 related articles for article (PubMed ID: 29795437)
21. FIGO Grade 3 Endometrioid Adenocarcinomas With Diffusely Aberrant β-Catenin Expression: An Aggressive Subset Resembling Cutaneous Pilomatrix Carcinomas.
Weisman P; Park KJ; Xu J
Int J Gynecol Pathol; 2022 Mar; 41(2):126-131. PubMed ID: 33811207
[TBL] [Abstract][Full Text] [Related]
22. Endometrial/Endometrioid Stromal Tumors With Extensive Whorling and CTNNB1 Translocation : A Report of 3 Cases.
Boyraz B; da Cruz Paula A; Deveraux KA; Tran I; da Silva EM; Young RH; Snuderl M; Weigelt B; Oliva E
Am J Surg Pathol; 2023 Nov; 47(11):1285-1290. PubMed ID: 37584555
[TBL] [Abstract][Full Text] [Related]
23. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of CTNNB1 mutation in early stage endometrial carcinoma: a systematic review and meta-analysis.
Travaglino A; Raffone A; Raimondo D; Reppuccia S; Ruggiero A; Arena A; Casadio P; Zullo F; Insabato L; Seracchioli R; Mollo A
Arch Gynecol Obstet; 2022 Aug; 306(2):423-431. PubMed ID: 35034160
[TBL] [Abstract][Full Text] [Related]
25. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
[TBL] [Abstract][Full Text] [Related]
26. Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.
Garcia-Rostan G; Camp RL; Herrero A; Carcangiu ML; Rimm DL; Tallini G
Am J Pathol; 2001 Mar; 158(3):987-96. PubMed ID: 11238046
[TBL] [Abstract][Full Text] [Related]
27. Assessment of CTNNB1 gene mutations and β-catenin immunoexpression in salivary gland pleomorphic adenomas and adenoid cystic carcinomas.
Cavalcante RB; Nonaka CFW; Santos HBP; Rabenhorst SHB; Pereira Pinto L; de Souza LB
Virchows Arch; 2018 Jun; 472(6):999-1005. PubMed ID: 29577164
[TBL] [Abstract][Full Text] [Related]
28. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations.
Konopka B; Janiec-Jankowska A; Czapczak D; Paszko Z; Bidziński M; Olszewski W; Goluda C
J Cancer Res Clin Oncol; 2007 Jun; 133(6):361-71. PubMed ID: 17219201
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
[TBL] [Abstract][Full Text] [Related]
30. CTNNB1 p.D32A (c.95A > C) somatic mutation in stage I grade 1 endometrioid endometrial carcinoma with lung metastasis: a case report.
Zhong L; Jiang W; RutieYin ; Liu H; Song L
BMC Med Genomics; 2023 Jun; 16(1):137. PubMed ID: 37328769
[TBL] [Abstract][Full Text] [Related]
31. Microcystic Stromal Tumor: A Distinctive Ovarian Sex Cord-Stromal Neoplasm Characterized by FOXL2, SF-1, WT-1, Cyclin D1, and β-catenin Nuclear Expression and CTNNB1 Mutations.
Irving JA; Lee CH; Yip S; Oliva E; McCluggage WG; Young RH
Am J Surg Pathol; 2015 Oct; 39(10):1420-6. PubMed ID: 26200099
[TBL] [Abstract][Full Text] [Related]
32. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
[TBL] [Abstract][Full Text] [Related]
33. An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
Kim Y; Ahn B; Yoon S; Lee G; Kim D; Chun SM; Kim HR; Jang SJ; Hwang HS
PLoS One; 2023; 18(6):e0287256. PubMed ID: 37347751
[TBL] [Abstract][Full Text] [Related]
34. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
35. Mutational analysis of the CTNNB1 (beta-catenin) gene in human endometrial cancer: frequent mutations at codon 34 that cause nuclear accumulation.
Ikeda T; Yoshinaga K; Semba S; Kondo E; Ohmori H; Horii A
Oncol Rep; 2000; 7(2):323-6. PubMed ID: 10671680
[TBL] [Abstract][Full Text] [Related]
36. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
37. Down-regulation of Sox7 is associated with aberrant activation of Wnt/b-catenin signaling in endometrial cancer.
Chan DW; Mak CS; Leung TH; Chan KK; Ngan HY
Oncotarget; 2012 Dec; 3(12):1546-56. PubMed ID: 23295859
[TBL] [Abstract][Full Text] [Related]
38. The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma.
Berger AA; Kawaler EA; Dao F; Misirlioglu S; Fernandez EA; Olvera N; Van Oudenhove E; DeLair D; Levine DA
Gynecol Oncol; 2022 Nov; 167(2):323-333. PubMed ID: 36150916
[TBL] [Abstract][Full Text] [Related]
39. Distinctive Patterns of CTNNB1 (β-Catenin) Alterations in Salivary Gland Basal Cell Adenoma and Basal Cell Adenocarcinoma.
Jo VY; Sholl LM; Krane JF
Am J Surg Pathol; 2016 Aug; 40(8):1143-50. PubMed ID: 27259009
[TBL] [Abstract][Full Text] [Related]
40. Clinicopathologic Evaluation of CTNNB1 Mutations in High-Intermediate Risk Endometrial Endometrioid Carcinoma.
Haag JG; Wolsky RJ; Moroney MR; Sheren J; Sheeder J; Bitler BG; Corr BR
Int J Gynecol Pathol; 2023 Jan; 42(1):43-53. PubMed ID: 35283443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
